Cure My Disease

Don't miss your cure!

 Log in / Sign up

What's it really like to wear a glucose monitor? a study asks patients

NCT ID NCT07019753

Knowledge-focused Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study explores the real-life experiences of adults with type 2 diabetes who have used a continuous glucose monitoring (CGM) device daily for at least a year. Through in-depth interviews, researchers aim to uncover the benefits and challenges people face with these devices. The findings could help healthcare providers offer more personalized support and inform decisions about expanding CGM use to more patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitoring (CGM) device
What this could lead to
If successful, this could help doctors and health systems understand how patients truly experience CGM devices, potentially leading to more personalized diabetes care and wider use of these devices.
What could go wrong
This is a very small study (5 participants) and is qualitative, so its findings may not represent the broader population. It does not test a treatment or measure clinical outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults in an industrialised country with a diagnosis of type 2 diabetes with intensive insulin regimen who have used a CGM device for at least the last 12 months. Participants will be recruited from primary care centres in the Camp de Tarragona health region following inclusion and exclusion criteria. Depending on the location of the primary care centre, the population may be from an urban, semi-urban, or rural setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have been using a CGM sensor daily for diabetes management for the past 12 months or more. * Treatment with intensive insulin therapy (basal bolus regimen with 3 or more daily doses of insulin). * Agree to participate in the study. Exclusion Criteria: * Cognitive impairment measured by the SPMSQ test with a score of 3 or more errors. * Being institutionalised. * Have another person responsible for monitoring the device and making decisions related to diabetes (insulin adjustment, carbohydrate rations, etc.). * Language difficulty: not being able to hold a fluent conversation in Catalan or Spanish for 30-60 minutes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Satisfaction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Patient satisfaction Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IDIAP Jordi Gol

    Barcelona, Barcelona, 08007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.